TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* - Histologically diagnosed HCC or HCC diagnosed according to the EASL criteria~* Measurable targets according to the mRECIST v1.1 criterion~* Preserved liver function (in case of Child-Pugh A or B7 cirrhosis)~* Tumour not subject to interventive care (liver transplant, surgical resection or percutaneous destruction)~* BCLC A/B without portal or extra-hepatic invasion~* No prior treatment by chemotherapy, radiotherapy or transarterial embolisation (with or without chemotherapy)~* Age ≥ 18 years~* WHO 0 or 1~* Laboratory test: platelets ≥ 50,000 mm3, N ≥ 1,000/mm3, creatininaemia ≤ 150 µmol/L, PT ≥ 50%~* No heart failure (isotope or ultrasound VEF \> 50%)~Exclusion Criteria:~* - Advanced tumour (vascular or extra-hepatic invasion including brain metastasis or diffuse HCC with liver invasion \> 50%)~* History of other type of cancer except cancer known to be in remission for more than 5 years (in this case, HCC histological proof is required), or basal-cell carcinoma or in situ cervix uteri cancer properly treated with curative treatment~* Advanced liver disease (Child B8, B9 and C, bilirubinaemia \> 3 mg/dL, SGOT and SGPT \> 5 x ULN or 250 U/L)~* Previous treatment by idarubicin and/or doxorubicin~* Idarubicin contraindications (cardiopathy with myocardial failure, serious kidney or liver failure, yellow fever vaccine)~* Concurrent disease or uncontrolled severe clinical condition~* Uncontrolled severe infection~* Patient requiring long-term anticoagulant treatment~* Thrombosis of the portal vein or a 3-segment region or more~* Hepatofugal portal venous flow~* Presence of serious atheromatosis~* Presence of collateral vascular ways potentially affecting the normal regions during embolisation~* Presence of arthritis of the hepatic artery branches to be treated~* Presence of arterioportal or arterial subhepatic fistula that cannot be embolised by coils~* Pregnancy or breastfeeding~* Absence of effective contraception (for men and women of childbearing age)~* Patient who cannot be regularly monitored on account of psychological, social, family- or geography-related reasons~* Concomitant participation of a patient in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DC-BEADS + Idarubicin (Type: EXPERIMENTAL): Chemoembolization with DC BEAD loaded with idarubicin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with suitable veins for cannulation or repeated venepuncture~* Pre-dose assessment judged without remarks by the investigator~* Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg~Exclusion Criteria:~* Abnormal vital signs, after 15 minutes supine rest, defined as any of the following:~* Systolic blood pressure \>140 mm Hg~* Diastolic blood pressure \>90 mm Hg~* Heart rate ≤45 or \>85 beats per minute~* Lack of normal phenotype for BuChE (Butyrylcholinesterase)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Intravenous solution given as a single ascending bolus dose
- 2 (Type: EXPERIMENTAL): Intravenous solution given as a single ascending bolus dose followed by a single infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute ankle sprain with a partial ligament tear within 48 hours of study entry~* At least moderate pain from the ankle sprain at baseline and before first dose of study medication~* In generally good health~* If female of childbearing potential, using acceptable method of birth control~Exclusion Criteria:~* Use of ibuprofen within 6 hours or topical pain relievers within 12 hours of study entry~* Use of tramadol HCl, tramadol HCl/acetaminophen, or hydrocodone bitartrate/acetaminophen within 30 days of study entry~* Use of epilepsy or antidepressant medications 3 weeks before the study entry~* Chronic use of pain medications or muscle relaxants for any reason during the study~* No use of steroid medications (oral or inhaled) on a chronic basis~* Required hospitalization to treat the ankle sprain~* Head trauma~* Pain greater than the pain caused by the ankle sprain~* Complete ligament tear~* Bone fractures on x-ray~* Required physical therapy, other than for crutch training~* History of kidney damage~* Pregnant or breast-feeding patients~* Condition that might affect the way the body absorbs or processes the study medication~* Major psychiatric disorder, history of attempted suicides/suicidal tendencies~* History of substance abuse or chronic alcohol abuse in the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Diagnosis of DED with Severe Keratitis who have not improved despite regular use of tear substitutes by an ophthalmologist, at least 2 months previously.~* Not stable (as defined by the two items below) under at least 2 months of constant and regular use of artificial tears (at least 4 drops a day)~* Fluorescein corneal staining ≥ 2 (Oxford scale) in both eyes.~* DEQ-5 \> 6 points~* Use of at least 4 times daily of an ocular artificial tears.~* Any concomitant medication that may affect DED, ocular surface condition or vision, must have a start date at least 3 months prior to baseline and dosage is not expected to change during the study.~* Best corrected visual acuity (BCVA) of at least 0.1 logMar at 6 meters with each eye.~* Signature of written informed consent form and data protection form.~Exclusion Criteria:~* Known allergy or sensitivity to the study product(s) or its components.~* Any ocular pathology other than DED.~* History of severe ocular inflammation other than that due to DED or infection in the 6 previous months to the study inclusion.~* Any ocular surgery or trauma that may affect corneal sensitivity and/or normal tear distribution in the 6 previous months or any ocular or systemic surgery or procedure planned during the study duration that may affect the study as assessed by principal investigator.~* History of refractive surgery in the previous 18 months.~* Contact lens use in the ONE previous month to study inclusion and during the duration of the study.~* Use of any ocular topical medication for pathologies other than DED.~* Use of any other ocular topical medication for DED other than artificial tears during the last ONE (steroids) or THREE months (ciclosporine, tacrolimus) .~* Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren's syndrome)~* The start date of any systemic medication that may affect DED, ocular surface condition or vision is \< 3 months prior to baseline or a change in dosage is anticipated during the study.~* Occlusion of the lacrimal puncta either surgically or with plugs within one month prior to study, or anticipated use of the same during the study.~* Pregnancy or breastfeeding.~* Current enrolments in an investigational drug or device study or participation in such a study within 30 day of entry into this study at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IKERVIS® (1mg/mL ciclosporin) eye drops (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of the Next-Generation Intraocular Lens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral cataracts~* Potential for postoperative BCDVA of 20/30 Snellen or better~* Corneal astigmatism of 1.00 D or less in both eyes~* Normal corneal topography~* Clear intraocular media other than cataract in each eye~* Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries~Exclusion Criteria:~* Any clinically-significant pupil abnormalities (non-reactive, fixed pupils, or abnormally-shaped pupils)~* Irregular corneal astigmatism~* Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)~* Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery~* Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/30 Snellen during the study~* Inability to achieve keratometric stability for contact lens wearers~* Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject~* Subjects with diagnosed degenerative visual disorders~* Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects~* Use of systemic or ocular medications that may affect vision~* Prior, current, or anticipated use of tamsulosin or silodosin~* Poorly-controlled diabetes~* Acute, chronic, or uncontrolled systemic or ocular disease or illness~* Known ocular disease or pathology that may affect visual acuity or may require surgical intervention during the course of the study or may be expected to require retinal laser treatment or other surgical intervention during the course of the study~* Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes~* Concurrent participation or participation within 45 days prior to preoperative visit in any other clinical trial~* Desire for monovision correction

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational Lens Device #1 (Type: OTHER): Investigational Intraocular Lens Device #1: Tecnis Model ZHR00
- Investigational Lens Device #2 (Type: OTHER): Investigational Intraocular Lens Device #2: Tecnis Model ZQR00
- Control Device (Type: OTHER): Control TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recently diagnosed type 2 diabetes (within 3 years) on diet or IGT~* Fasting triglyceride levels \>140 and \< 400 mg/dl and values varying less than 35% between two screening measurements~* Normal liver function tests and white blood cell count~Exclusion Criteria:~* Type 2 Diabetes for \> 3 years or HbA1c ≥ 7.5~* Known or suspected Type 1 Diabetes~* Any diabetes medications in the past 3 weeks, TZD in the prior 3 months or prior regular use of insulin~* Creatinine \> 2.0 mg/dl or other evidence of active kidney disease~* Hepatic enzyme elevation \> 2x normal~* Known Nonalcoholic Fatty Liver Disease~* Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems~* Recent history of nausea or vomiting~* Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks~* A prior cardiovascular event, stable or unstable angina or other major illness in the past 6 months~* Current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (\>1 g/day)~* Any lipid lowering therapy in the prior 3 weeks other than a statin medication. Subjects receiving a statin medication must be on a stable dose for at least 2 months prior to participation.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult aged 18-55 years.~* Normal medical history and physical examination.~* Normal urine dipstick, blood count, liver enzymes, and creatinine.~Exclusion Criteria:~* Exposure to TB at any point. Previous residence in a TB endemic area.~* Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness, psychiatric disorder, drug or alcohol abuse.~* Oral or systemic steroid medication or the use of immunosuppressive agents.~* Positive HIV antibody test, HCV antibody test or positive HBV serology except post-vaccination.~* Heaf test greater than Grade II~* Confirmed pregnancy~* Previous MVA immunisations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18-70 years~* Patients diagnosed with CKD (Estimated Glomerular Filtration Rate (eGFR) \>15 mL/min/1.73 m\*2) and hypertension without dialysis/replacement therapy~* Patients with uncontrolled hypertension (office SBP ≥140 mmHg and DBP ≥ 80 mmHg) who have received Renin-Angiotensin System Inhibitors (RASI) treatment or have not received RASI treatment because of any contraindications~* Patients who haven't received nifedipine GITS 60 mg (once per day) previously~* Patients for whom the decision to initiate treatment with nifedipine GITS 60 mg was made as per the investigator's routine treatment practice~* Signed informed consent~* No participation in an investigational program with interventions outside of routine clinical practice~Exclusion Criteria:~* Have a contraindication to nifedipine GITS according to the approved prescribing information~* Patients participating in an investigational program with interventions outside of routine clinical practice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040) (Type: None): Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of idiopathic Parkinson's Disease~* Subject has been on continuous treatment with commercially available Rotigotine transdermal patches (Neupro®) for at least 3 months prior to enrollment~* Subject has been taking a stable Rotigotine dose including an 8 mg/24 hours (40 cm\^2) patch for at least 2 weeks prior to enrollment~Exclusion Criteria:~* Subject has any medical or psychiatric condition which, in the opinion of the investigator, could jeopardize or would compromise the subject's well-being or ability to participate in this study~* Subject has a history of significant skin hypersensitivity to adhesives or other transdermal products or recently unsolved contact dermatitis~* Subject has a history or present condition of an atopic or eczematous Dermatitis, Psoriasis, or an active skin disease~* Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('yes') to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening (Visit 1) or Baseline (Visit 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm A-B (Type: EXPERIMENTAL): 4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
- Treatment Arm B-A (Type: EXPERIMENTAL): 4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on to Micamlo BP Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be \>=90 and \<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\<200 mmHg~* Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion~* Age 20 years or older~Exclusion criteria:~* Patients with known or suspected secondary hypertension~* Patients with clinically relevant cardiac arrhythmia~* Congestive heart failure with New York Heart Association (NYHA) functional class III-IV~* Patients with recent cardiovascular events~* Patients with recent stroke events~* Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy~* Patients with hepatic and/or renal dysfunction~* Pre-menopausal women who are nursing or pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Telmisartan+amlodipine+HCTZ (Type: EXPERIMENTAL): telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
- Telmisartan+amlodipine (Type: ACTIVE_COMPARATOR): telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Endostatin and Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer diagnosis and fine needle aspiration for lymph node metastasis diagnosis)~* Stage ⅡA-ⅢC~* Age 18-70~* ECOG performance status 0-2~* No evidence of distant metastasis~* No previous therapy~* Normal hematologic function~* left ventricular ejection fraction greater than 50 percent~* No abnormality of renal or liver function~* Written informed consent~Exclusion Criteria:~* With allergic constitution or possible allergic reflection to drugs to be used in this study~* Any concurrent uncontrolled medical or psychiatric disorder~* History of severe heart diseases, including congestive heart failure, unstable angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or heart valve disease.~* History of bleeding diathesis~* Being pregnant or nursing

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: ACTIVE_COMPARATOR): neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
- chemotherapy plus endostatin (Type: EXPERIMENTAL): neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete